Identification, design, and in vivo proof of concept of a shared APC neoantigen delivered via a self-amplifying RNA containing virus-like nanoparticle for cancer vaccination
By
Alfred J. Simmons
Anna S. Nikonova
Chloe D. Jonas
Katherine A. Pniewski
Deepak Upreti
Maria I. Perez
Satish Adhikari
June 4, 2026
Clinical Scorecard: Development and validation of a shared APC neoantigen using a self-amplifying RNA virus-like nanoparticle for cancer immunotherapy
At a Glance
Category Detail
Condition Colorectal Cancer (CRC) and Familial Adenomatous Polyposis (FAP) Key Mechanisms APC gene mutations leading to Wnt pathway hyperactivation and uncontrolled cell growth. Target Population Patients with APC gene mutations, particularly those with FAP. Care Setting Oncology and genetic counseling.
Key Highlights
Over 80% of CRC cases are caused by mutations in the APC gene. FAP is characterized by numerous adenomatous polyps and a near 100% risk of CRC. The study developed a virus-like particle to deliver neoantigens targeting APC mutations. In vitro T-cell activation was observed against neoantigen peptide fragments. Significant immune response was confirmed in vivo with neoantigen-specific IgG titers. Guideline-Based Recommendations
Diagnosis
Genetic testing for APC mutations in patients with a family history of FAP. Management
Regular surveillance and management of polyp development in FAP patients. Monitoring & Follow-up
Monitoring for adenocarcinoma development in patients with FAP. Risks
High risk of CRC development in patients with inherited APC mutations. Patient & Prescribing Data
Individuals with APC mutations and FAP.
Vaccines targeting APC mutations may provide a preventative approach for CRC.
Clinical Best Practices
Utilize bioinformatics to identify neoantigen epitopes in APC mutations. Consider vaccination strategies using virus-like nanoparticles for APC-associated CRC. Related Resources & Content
